Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

F15063

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
RationaleThere is increasing interest in antipsychotics intended to manage positive symptoms via D2 receptor blockade and improve… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
2009
2009
Brain region-specific modulation of immediate-early gene (IEG) may constitute a marker of antipsychotic drug-like activity. We… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2009
2009
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-ethyl]-(3-cyclopenten-1-yl-benzyl)-amine) is a potential antipsychotic… Expand
2008
2008
Several novel antipsychotics activate serotonin 5-HT1A receptors as well as antagonising dopamine D2/3 receptors. Such a… Expand
2008
2008
Interaction at dopamine D4 receptors may improve cognitive function, which is highly impaired in individuals with schizophrenia… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2008
2008
Small rodents (mice, rats) are the species of choice for evaluating the pharmacology of centrally acting compounds, such as… Expand
  • figure 1
  • figure 2
Highly Cited
2007
Highly Cited
2007
The D2/D3 receptor antagonist, D4 receptor partial agonist, and high efficacy 5‐HT1A receptor agonist F15063 was shown to be… Expand
2007
2007
F15063 is a high affinity D2/D3 antagonist, D4 partial agonist, and high efficacy 5‐HT1A agonist, with little affinity (40‐fold… Expand
2007
2007
Combining 5‐HT1A receptor activation with dopamine D2/D3 receptor blockade should improve negative symptoms and cognitive… Expand
2007
2007
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3